PharmacyCodes



Methylphenidatum [Inn-Latin] en es it fr

Methylphenidatum [Inn-Latin] Brand names, Methylphenidatum [Inn-Latin] Analogs

Methylphenidatum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Methylphenidatum [Inn-Latin] Chemical_Formula

C14H19NO2

Methylphenidatum [Inn-Latin] RX_link

http://www.rxlist.com/cgi/generic/methphen.htm

Methylphenidatum [Inn-Latin] fda sheet

Methylphenidatum_[Inn-Latin] FDA

Methylphenidatum [Inn-Latin] msds (material safety sheet)

Methylphenidatum_[Inn-Latin] MSDS

Methylphenidatum [Inn-Latin] Synthesis Reference

M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)

Methylphenidatum [Inn-Latin] Molecular Weight

233.306 g/mol

Methylphenidatum [Inn-Latin] Melting Point

224-226oC

Methylphenidatum [Inn-Latin] H2O Solubility

1255mg/L

Methylphenidatum [Inn-Latin] State

Solid

Methylphenidatum [Inn-Latin] LogP

3.192

Methylphenidatum [Inn-Latin] Dosage Forms

Tablets; Tablets (sustained release)

Methylphenidatum [Inn-Latin] Indication

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Methylphenidatum [Inn-Latin] Pharmacology

Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Methylphenidatum [Inn-Latin] Absorption

Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)

Methylphenidatum [Inn-Latin] side effects and Toxicity

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)

Methylphenidatum [Inn-Latin] Patient Information

Methylphenidatum [Inn-Latin] Organisms Affected

Humans and other mammals